US outbound investment curbs threaten Chinese biotech licensing surge

Washington's proposed outbound investment restrictions, though not directly targeting drug licensing, could complicate Chinese biotech firms' access to US capital and joint ventures, potentially slowing their global expansion. The draft rules from the US Treasury, released last week, add regulatory uncertainty to a sector that has seen a surge in licensing deals. The impact hinges on final rule scope and enforcement, with analysts noting the measures could reshape deal structures.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works